<DOC>
	<DOCNO>NCT00470210</DOCNO>
	<brief_summary>This trial ass sustain virologic response treatment peginterferon alfa-2a combine high-dose ribavirin human immunodeficiency virus ( HIV ) -infected patient hepatitis C virus ( HCV ) genotype 1 4 coinfection persistent transaminase elevation . These patient nonresponders previous regimen peginterferon alfa ribavirin therapy dosage 800-1200 mg/d .</brief_summary>
	<brief_title>Peginterferon Alfa-2a , Ribavirin Epoetin Î² Coinfected Patients HCV/HIV Not Responding Previous Treatment Regimens</brief_title>
	<detailed_description>The purpose treat chronic HCV infection HIV-coinfected individual clear HCV-RNA antibody cure infection . Studies show high dos ribavirin associate high response rate achieve ribavirin dosage 800-1200 mg/d . The main aim trial ass sustain virologic response treatment peginterferon alfa-2a plus high-dose ribavirin HIV-infected patient coinfected HCV genotype 1 4 persistent transaminase elevation lack response previous treatment peginterferon alfa ribavirin dosages 800-1200 mg/d . The second aim measure change serum HCV-RNA titer percentage patient achieve serum viral load &lt; 50 IU/mL treatment . Finally , also intend evaluate safety treatment regimen .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>HIVinfected patient coinfected HCV genotype 1 4 Persistent transaminase elevation Nonresponders previous treatment peginterferon alfa plus ribavirin dosage 8001200 mg/d . Patients abandon treatment peginterferon plus ribavirin 12 week Patients ChildPugh B C cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>non-responders</keyword>
	<keyword>HCV co-infected patient</keyword>
	<keyword>sustained virological response</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>